Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Payables (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Payables for 4 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Payables rose 18.72% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, up 18.72% year-over-year, with the annual reading at $6.1 million for FY2025, 18.72% up from the prior year.
  • Payables for Q4 2025 was $6.1 million at Orchestra BioMed Holdings, down from $8.5 million in the prior quarter.
  • The five-year high for Payables was $8.5 million in Q3 2025, with the low at $103607.0 in Q1 2022.
  • Average Payables over 4 years is $3.8 million, with a median of $3.7 million recorded in 2022.
  • Peak annual rise in Payables hit 2568.74% in 2023, while the deepest fall reached 26.92% in 2023.
  • Over 4 years, Payables stood at $4.0 million in 2022, then dropped by 26.92% to $2.9 million in 2023, then soared by 77.03% to $5.1 million in 2024, then rose by 18.72% to $6.1 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $6.1 million, $8.5 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.